FIP guidelines for dissolution testing of solid oral products (final draft, 1995): Joint report of the Section for Official Laboratories and Medicines Control Services and the Section of Industrial Pharmacists

Drug Information Journal

Volumn 30, Issue 4, 1996, Pages 1071-1084

  Siewert, Martin ^a  

^a SANOFI   (France)

Author keywords

Dissolution testing; FIP; In vitro In vivo; Solid oral products

Indexed keywords

APPARATUS; BIOEQUIVALENCE; CALIBRATION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG RELEASE; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; MEDICAL LITERATURE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PHARMACOKINETICS; POWDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; REVIEW; SUPPOSITORY; SUSTAINED RELEASE PREPARATION;

EID: 0000655208     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000424     Document Type: Review

References (42)

1. FIP Guidelines for Dis solution Testing of Solid Oral Products. Pharm Ind. 1981;43:334-343.
2. Pernarowski M. Dissolution Methodology. In Leeson LJ, Carstensen JT (Eds.). Dissolution Technology. Washington, DC; APhA: 1974.
3. Krowczynski L. Kritischer Vergleich von Geräten und Methoden zur Bestimmung der Auflösungsgeschwindigkeit von Tabletten. Pharmazie. 1978;33:241-247.
4. Dakkuri A, Shak AC. Dissolution Methology: an Overview. Pharm Technol. 1982;2:41-53.
5. Lathia CD, Banakar WV. Advances in Dissolution Technology: Design, pros and cons. Drug Dev Ind Pharm. 1986;12:71-105.
6. Siewert M. Associations and Specifications. In Blume H, Grundert-Remy U, Möller H (Eds.) Controlled/Modified Release Products. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1991.
7. Wells CE. Effect of Sampling Probe Size on Dissolution of Tableted Drug Samples. J Pharm Sci. 1981; 70:232-233.
8. Stricker H. Optimierung und Justierung der Versuchsbedingungen von in vitro-Tests: Feste perorale Arzneizubereitungen. Acta Pharm Technol. 1984;30:113-125.
9. Stricker H. In-vitro-Studien zum Auflöse- und Resorptionsverhalten oral verabreichter Arzneistoffe und die Korrelation mit der biologischen Verfügbarkeit. Pharm Ind. 1976;38:232-234.
10. Dibbern HW. Verfügbarkeitsprüfung in vitro: Forderungen, Möglichkeiten, Grenzen. Pharm Ind. 1984; 46:381-385.
11. Das SK, Gupta BK. Simulation of physiological pH-time profile in in vitro dissolution study: Relationship between dissolution rate and bioavailability of controlled release dosage form. Drug Dev Ind Pharm. 1988;14:537-544.
12. Blume H, Ali SL, Siewert M. Zur pharmazeutischen Qualität von glibenclamidhaltigen Fertigarzneimitteln. Pharm Ztg. 1984;129:983-989.
13. EEC Note for Guidance. Quality of Prolonged Release Oral Solid Dosage Forms. 1991.
14. Guidelines for Design and Evaluation of Oral Sustained Release Dosage Form. Ministry of Health and Welfare of Japan. Yakuskin-1-5; 1988.
15. Workshop Report In Vitro and In Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms. Pharm Res. 1990;7:975-982.
16. Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. In Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants. Pharm Res. 1989;6(7):612-618.
17. Shah VP, Gurbarg M, Noory A, Dighe S, Skelly JP. Influence of Higher Rates of Agitation on Release Patterns of Immediate-Release Drug Products. J Pharm Sci. 1991;81(6):500-503.
18. 〈1088〉 In-vitro and in-vivo evaluation of dosage forms USP 23;1995.
19. Qureshi SA, McGilveray U. Impact of Different Deaeration Methods on the USP Dissolution Apparatus Suitability Test Criteria. Pharm Forum. 1994;20(6): 8565-8566.
20. Soltero RA, Hoover JM, Jones FT, Standish M. Effects of Sinker Shapes on Dissolution Profiles. J Pharm Sci. 1898;78:35-39.
21. U.S. Pharmacopeia 23, Supplement 1: Drug Release 〈724〉 2535; 1995.
22. Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm Ind. 1982;44:1166-1172.
23. Langenbucher F. Improved algorithms correlating body response with drug input. Pharm Ind. 1982; 44:1275-1278.
24. Wagner JW, Nelson F. Percent absorbed time plots derived from blood level or urinary excretion data. J Pharm Sci. 1963;57:918-928.
25. Loo JCK, Riegelmann S. New method for calculating the intrinsic absorption rate of drug. J Pharm Sci. 1968;57:918-928.
26. Brockmeier D, Voegele D, von Hattingberg HM. In vitro-in vivo correlation, a time scaling problem? Arzneimittelforschung. 1983;3 33:598-601.
27. von Hattingberg HM. Momenten-Analyse und in vitro/in vivo Korrelation. Acta Pharm Technol. 1984;30:93-101.
28. Cardot JM, Beyssac E. In vitro/in vivo Correlations: Scientific Implications and Standardisation. Eur J Drug Metab Pharmacokinet. 1993;18(1):113-120.
29. Siewert M. Presentation given at BIO-International '94 pre-conference satellite. 1994.
30. Workshop Report: Scale-Up of Immediate Release Oral Solid Dosage Forms. Pharm Res. 1993;10:313-316 and Eur J Pharm Biopharm. 1993;39(1):40-43.
31. Workshop Report: Scale-Up of Immediate Release Oral Solid Dosage Forms. Pharm Res. 1993;10:313-316 and Eur J Pharm Biopharm. 1993;39(1):40-43.
32. Workshop II Report: Scale-Up of Oral Extended Release Dosage Forms. Pharm Res. 1993;10:1800-1805 and Eur J Pharm Biopharm. 1993;39(4):162-167.
33. Workshop II Report: Scale-Up of Oral Extended Release Dosage Forms. Pharm Res. 1993;10:1800-1805 and Eur J Pharm Biopharm. 1993;39(4):162-167.
34. FDA Immediate Release Scale-up and Post Approval Change (SUPAC) Expert Working Group of the Chemistry Manufacturing Controls Coordinating Committee of the Center for Drug Evaluation and Research (1994) Interim Guidance Immediate Release Solid Oral Dosage Forms - Pre- and Post-Approval Changes. 1994.
35. Maturu PK, Prasad VK, Worsley W, Shiu GK, Skelly JP. Influence of a high fat breakfast on the bioavailability of theophylline controlled-release formulations: an in vitro demonstration of an in vivo observation. J Pharm Sci. 1986;75:1205-1206.
36. Wearly L, Karim A, Pagone F, Streicher J, Wickman A. Food-Induced Theophylline Release/Absorption Changes from Controlled-Release Formulations: A Proposed in Vitro Model. Drug Devl Ind Pharm. 1988;14:13-28.
37. Karim A. Importance of Assessing Food Effects in Evaluating Controlled-Release Formulations. (1988) In: Yacobi A und Halperin-Walega E. Oral Sustained Release Formulations: Design and Evaluation. New York: Pergamon Press; 1988;157-181.
38. El-Arini K, Shiu GK, Skelly JP. Theophylline-Controlled Release Preparations and Fatty Food: An in vitro Study Using the Rotating Dialysis Cell. Pharm Res. 1990;7:1134-1140.
39. Macheras P, Koupparis M, Tsaprounis C. Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique. Int J Pharm. 1986;33:125-136.
40. Junginger HE, Verhoeven J, Peschier LJC. Eine neues in vitro-Modell zur Erkennung von Wechselwirkungen zwischen Retardarzneimitteln zur oralen Applikation und Nahrungsmitteln. Pharm Ztg Wiss. 1990;2:53-58.
41. Krämer J, Lindauer RF, Siewert M, Stricker H, Blume H. Extended-Release Theophylline Alternative In Vitro Dissolution Methods. Eur J Drug Metab Pharmacokin. 1993;18:37.
42. Siewert M. In vitro-Dissolution Testing of Oral Controlled Release Products. In: Gundert- Remy U und Möller H. Oral Controlled Release Products Therapeutic and Biopharmaceutic Assessment. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft: 139-154.